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Abstract
Background: Erythropoiesis-stimulating agents (ESAs) are commonly used for the treatment of anemia due to
chronic kidney disease (CKD) and end stage renal disease (ESRD). Patients often lack an understanding of the
potential risks and benefits of ESAs, despite government mandated education on this topic. Decision aids are tools
commonly used to discuss important information in health care settings. To address this knowledge gap, we
designed this study to evaluate the effectiveness of a novel ESA decision aid at promoting informed shared
decision making (ISDM) between patients and providers related to ESA use for CKD- and ESRD-related anemia.
Methods: Using the principles of informed shared decision making theory, we designed and piloted an ESA
decision aid intended to increase CKD and ESRD patient understanding of the potential risks and benefits of ESAs.
Informed by the findings during development, the ESA decision aid was modified and finalized for testing. We will
perform a randomized clinical trial to assess if administration of the ESA decision aid improves patient
understanding of the risks and benefits of ESA use compared to control patients receiving standard care.
Participants with either CKD or ESRD and who are receiving ESAs will be eligible for participation. The primary
outcome is patients’ score on the Patient Anemia Knowledge in Kidney Disease (PAKKD) survey assessed at
enrollment and 3 months after. Secondary outcomes include decisional conflict related to ESAs, and patient
satisfaction with provider communication.
Discussion: The Anemia Risk Communication for patients with Kidney Disease (ARC-KD) study will assess the
effectiveness of a novel ESA decision aid to improve patient understanding of ESA use to manage CKD- and
ESRD-related anemia. This decision aid is the first resource targeted to improve patient understanding of anemia
management in the kidney health context. With the increasing options available for anemia management, this will
serve as an important foundation to evolve in the future to optimize anemia-related shared decision making.
Trial registration: ClinicalTrials.gov, number NCT01992926. Registered 11/14/2013.
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Background
Anemia affects nearly 95 % of patients receiving dialysis
and 15 % of those with chronic kidney disease (CKD)
[1]. Erythropoiesis-stimulating agents (ESAs) have been
used for the past two decades to treat the complications
of anemia in patients with kidney disease. The inability
of ESAs to improve patient-reported outcomes, such as
fatigue, in clinical trials has cast doubt on the potential
benefits of ESAs relative to their risks, which include a
near doubling of risk for stroke [2]. In March 2010, the
Food and Drug Administration (FDA) required the ad-
ministration of medication guides to patients receiving
ESAs to improve their understanding of the potential
risks and benefits of ESA treatment [3]. Unfortunately,
these basic tools may not adequately educate patients
thoroughly about the risks and benefits of ESA therapy.
Even patients with kidney disease who frequently visit
their nephrologists have knowledge deficits about their
disease and the role of the kidney in anemia [4]. This is
likely in part because communication is difficult from
both the patient and the physician perspectives, and this
is amplified when discussing possible risks [5].
Informed shared decision making (ISDM) has
emerged as a leading evidence- based theory that,
when applied successfully, can improve patient-
provider communications surrounding health risks [6].
Best-practice ISDM requires the provider to initiate
conversations by introducing the concept of patient
choice, describe the options of care available to pa-
tients, often by employing a decision aid, and help
patients better define their preferences to make good
health care decisions [7]. The Ottawa Decision Sup-
port Framework, an evidence-based set of guidelines
used in the development and evaluation of over 30
empirically derived decision aids, also requires that
the ISDM process be critically evaluated for quality
and its impact on health outcomes [8, 9]. Decision
aids developed by systematically applying ISDM the-
ory can help to reinforce consistent application of
ISDM principles during the health care decision mak-
ing process [10].
In this study, we sought to develop and evaluate a de-
cision aid for ESA therapy to be administered to ESRD
and CKD patient populations. We hypothesized that the
use of an ESA decision aid that follows the International
Patient Decision Aid Standards (IPDAS) [11] and ad-
heres to expert opinion for optimizing communication
with low health literacy and numeracy patients [12] will
increase patient knowledge of anemia in kidney disease,
reduce patient uncertainty related to ESA use, and in-
crease overall patient care satisfaction. We also
hypothesize that these effects might be enhanced for
vulnerable patient populations, who stand to benefit
from these improvements the most [12, 13].
Methods and study design
Study design summary
The Anemia Risk Communication for patients with Kid-
ney Disease (ARC-KD) study is a two-phase study to de-
sign, test, and optimize a novel decision aid to improve
ISDM and patient understanding regarding the use of
ESAs for treatment of anemia in chronic kidney disease
(Fig. 1). In Phase 1, we designed, revised, and usability-
tested a one-page ISDM-informed ESA decision aid
intervention. In Phase 2, we will conduct a randomized
controlled trial to assess the effectiveness of the revised
ESA decision aid at improving CKD and ESRD patient
knowledge and decision making about anemia manage-
ment using ESAs.
Phase 1a: development of the ESA decision aid
To prepare for Phase I implementation, we conducted a
literature review to support the development of the ESA
decision aid. We focused our search on papers that de-
scribed theories of ISDM in medical practice using the
Ottawa Decision Support Framework. We also reviewed
examples of high quality decision aids in the Decision
Aid Library Inventory (DALI) available online via the
Ottawa Hospital Research Institute [14]. This search
revealed limited research and resources describing
kidney-specific decision aids and none describing anemia
management decision aids, kidney health related or
otherwise [13]. Importantly, however, we did find evi-
dence that the application of ISDM principles to patient-
provider communications can improve health knowledge
and outcomes in CKD and ESRD patient populations,
including in patient sub-populations with low health lit-
eracy and numeracy [12].
This search led us to consider the IPDAS quality do-
mains as guiding principles when developing the ESA
decision aid [11]. These domains define high quality de-
cision aids as those that [1] [involve a] systematic devel-
opment process [2] provide information about options
[3] present probabilities [4] clarify and express values [5]
use patient stories [6] guide or coach [patients and pro-
viders] in deliberation and communication [7] disclose
conflicts of interest [8] deliver patient aids on the inter-
net [9] balance presentation of options [10] use plain
language [11] base information on up to date scientific
evidence and [12] establish effectiveness [11]. The mini-
mum quality domains and standards necessary to certify
high-quality, ISDM-informed decision aids under the
IPDAS framework are still undergoing consideration and
are not yet defined [15].
The resulting draft ESA decision aid (Fig. 2) included
6 sections numbered to indicate the order in which the
ESA decision aid should be administered. On its face,
the systematically developed (IPDAS criterion 1) draft
ESA decision aid contained sections that required the
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patient and provider to set shared goals (IPDAS criterion
6) (Section 1); encouraged the patient to engage inter-
actively with the aid to facilitate individual consideration
of acceptable treatment risk vs. quality of life benefits
(IPDAS criteria 4) (Sections 2 and 6); helped the patient
learn basic facts about anemia (IPDAS criteria 2, 9 and
11) (Sections 1–3); helped the patient understand the
probability-based risks and benefits of ESAs to treat
anemia and the resulting potential impacts on quality of
life (IPDAS criterion 3) (Sections 4 and 5); and allotted
space for the patient to make a care related decision re-
garding whether or not to use ESAs (when trial data is
evaluated, will contribute toward achieving IPDAS cri-
terion 12) (Section 6). Additionally, the ESA decision aid
used plain language and was drafted at a seventh grade
reading level to facilitate comprehension of the aid by all
patients, including those with low health literacy (IPDAS
criteria 10) [12]. In total, the draft ESA decision aid met
9 of the 12 quality domains from the 2006 IPDAS deci-
sion aid checklist.
The IPDAS domains not addressed by the draft deci-
sion aid were “5. using patient stories”, “7. disclosing
conflicts of interest” and “8. delivering patient aids on
the internet.” We chose not to include an individual pa-
tient story due to concerns that variability in the degree
individual patients related to the patient in the story
could bias patient decision-aid assisted decision-making
results [11, 16]. Though the aid does not state it, no con-
flict of interest exists for any person who developed the
decision aid. Lastly, because our trial planned to deliver
the decision aid in person for research purposes, it was
not made available online.
To further evaluate the quality of the draft ESA deci-
sion aid, we engaged patients and providers to review
the usefulness and accessibility of the tool, in accordance
with recent decision aid best practices [10]. A
Fig. 1 ARC-KD Study Planning Diagram. Phase 1 (left side). Development of the ESA decision aid. Phase 2 (right side) randomized clinical trial to
evaluate effect of ESA decision aid
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Fig. 2 (See legend on next page.)
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convenience sample of 18 nephrology medical providers
and 39 patients with kidney disease at Vanderbilt Uni-
versity Medical Center provided feedback on the draft
ESA decision aid. Patients providing feedback had a
CKD or ESRD diagnosis, were at least 18 years of age,
were receiving ESAs for anemia, spoke English, and had
no significant visual impairment. No compensation was
given to participants.
Patients and providers independently reviewed printed
copies of the ESA decision aid and completed a 17-
question survey to provide feedback about the design and
usefulness of the ESA decision aid at promoting informed
shared decision making. Results from the surveys were
compiled and used to revise the ESA decision aid.
Phase 1b: revision of the ESA decision aid
Review and analysis of the survey feedback showed ap-
proximately half of patients and providers alike felt sig-
nificant revisions to Sections 1, 2 and 4 of the draft
decision aid were warranted. In Section 1 (presentation
of healthy hemoglobin levels), patients described the in-
clusion of hemoglobin values for “normal” patients with-
out kidney disease as stigmatizing. Generally, patients
reported they found the graphs in Sections 1 and 2
(presentation of target hemoglobin levels for patients
with kidney disease) to be more confusing than the in-
formational sections of the decision aid. Likewise, pro-
viders predicted that such confusion about graphical
interpretation may occur among patients. In response to
this feedback, we revised Sections 1 and 2 of the deci-
sion aid to only include graphs containing pictorial rep-
resentations of hemoglobin levels observed in CKD and
ESRD patients (Figs. 2 and 3).
Additionally, both patients and providers expressed
confusion about the use of smile face icons in Section 4
(pictorial representation of stroke risk due to ESA use)
to represent symbolically the probability of adverse
events due to ESA use. Patients reported these symbols
were a poor choice to symbolize risk, because they asso-
ciated smile faces with positive rather than with adverse
health outcomes. In response, the revised ESA decision
aid included solid dots in the pictograph (Fig. 3).
Phase 1c: usability testing of the ESA decision aid
After revision, the ESA decision aid was evaluated for
usability with the Suitability Assessment of Materials
(SAM) survey [17]. SAM scores of 70–100 are superior,
scores of 40–69 are adequate, while scores less than 40
are inadequate. Previous evaluation of 69 kidney disease
patient education materials found a mean overall usabil-
ity score of 58 % [17]. The ESA decision aid SAM score
for the revised ESA decision aid was 89 %, demonstrat-
ing a superior mean SAM usability score. The next
phase of this study will test this version of the decision
aid informed by both provider and patient stakeholders.
Phase 2: randomized controlled trial evaluating the use of
an ESA decision aid to improve patient anemia
knowledge
To evaluate the ESA decision aid in practice, we will
conduct a randomized controlled trial of 100 patients.
The trial will utilize validated survey tools and measures
to determine if the primary and secondary outcomes of
increased patient knowledge and patient satisfaction
with ESA use decision have been met, respectively
(Table 1).
Following informed consent, ARC-KD study partici-
pants will complete the indicated survey metrics during
at least one of three possible time points: enrollment
(Baseline Pre-Visit), up to one week after the baseline
enrollment visit (Post-Visit) and three months after en-
rollment (Three Months). Study staff will obtain
hemoglobin lab values from each participant’s electronic
health care record at baseline and three months.
Target population and eligibility criteria
Planned recruitment criteria for study participants in-
clude diagnosis of CKD or ESRD, current ESA therapy,
age between 18 and 80, and English fluency. Patients will
be excluded if they have significant cognitive impairment
or visual impairment. Cognitive impairment will be de-
termined by asking patients to complete the Mental
Status Assessment of Older Adults, or Mini-Cog [18].
Participants will be excluded if they do not speak
English, due to a lack of available staff to translate.
Recruitment of participants
Participants will be recruited from the in-center and
home dialysis clinics at Vanderbilt University Medical
Center, as well as the outpatient nephrology clinic at the
Vanderbilt Clinic. Potential participants will be identified
by an examination of their electronic medical record.
(See figure on previous page.)
Fig. 2 Draft ESA Decision Aid. The draft ESA decision aid contains 6 sections organized to be delivered to patients from right to left, then top to
bottom. The “Men” and “Women” bars in Sections 1 and 2 represent the hemoglobin levels of individuals without kidney disease, while the “too
high” and “too low” bars represent the high and low ranges of hemoglobin levels for individuals with kidney disease, respectively. Section 3
includes information to educate patients about the impact of anemia on patient health and wellness. Section 4 presents the potential health risks
of using ESAs to manage anemia, while Section 5 presents the potential benefits. Section 6 contains checkboxes to assist patients with planning
their future ESA use
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Patients will be actively recruited by a study coordinator
who will approach eligible individuals, explain the con-
tent of the study, and answer any questions the individ-
ual may have. Written informed consent will be
obtained from all participants. Reminder phone calls and
appointment cards are given to patients at all clinics par-
ticipating in the study to increase patient appointment
attendance. These methods will also be used to increase
retention of study participants, who will receive the
intervention or control usual care during a pre-
scheduled patient appointment.
Randomization
Using blind and secure allocation, participants will be
randomly assigned to one of two intervention arms: 1.)
the usual care control group, or 2.) the ESA decision aid
intervention group. Randomization will not be blocked
by site, due to recruitment from within one large neph-
rology practice. The allocation sequence will be
computer-generated. Participants will be recruited and
assigned to intervention groups by the study coordin-
ator, who will be blind to the allocation sequence. After
assignment trial participants and care providers not in-
volved in the study will not be blinded to the
assignment.
Usual care group
Participants who are randomly assigned to the control
group will receive standard care from their existing ne-
phrologists, nurses, and clinical staff. As all of the partic-
ipants in the study will be receiving ESA therapy, this
care may include a description of the purpose of the
medication by the staff member administering the injec-
tion and counseling about its purpose and potential
risks, but without use of the ESA decision aid.
Intervention group
Participants randomly assigned to the intervention
group will receive a paper copy of the ESA decision aid
(Fig. 3). This decision aid will be administered by and
discussed with a nephrology nurse practitioner, who will
explain the purpose and function of ESA’s, the goal
hemoglobin levels for those receiving ESAs, the positive
and negative effects of the medication, and additional re-
sources available to patients. In order to maintain
consistency across the clinics, the same nurse practi-
tioner will administer the decision aid tool to all inter-
vention participants across the dialysis clinics. Similarly,
a nurse in the CKD clinic that is assigned to anemia
management will be responsible for administering the
ESA decision aid. Each of these clinical personnel will be
(See figure on previous page.)
Fig. 3 Revised ESA Decision Aid. The revised ESA decision aid contains 6 sections organized to be delivered to patients from top to bottom.
Section 1 explains the mechanism for how and why ESAs are used to treat anemia in kidney disease patients. Section 2 raises patient awareness
of their current hemoglobin level and encourages them to set a new goal hemoglobin level with their providers. Section 3 presents the benefits
of ESAs, while Section 4 presents the risks. Section 5 contains additional information to help patients understand the impact of their decision to
use ESAs on downstream treatment options related to broader kidney health outcomes. Section 6 includes checkboxes to assist patients with
planning their future ESA use
Table 1 Study outcomes, measures, and patient characteristics
No. Outcomes, Measures
& Characteristics
Data Source by Outcome Timeline and Frequency
Baseline Pre-Visit Post-Visit Three Months
1 Primary Outcome Patient Knowledge
Anemia Knowledge Patient Anemia Knowledge in Kidney Disease (PAKKD) [19] X X X
2 Secondary Outcomes Patient Satisfaction
Provider Communication Satisfaction Satisfaction with Provider Communications (CAT) [20] X
Health Decision Certainty Decisional Conflict Scale (DCS) [21] X
Perceived Communication Efficacy Perceived Efficacy in Patient-Physician Interactions
(PEPPI) [22]
X X
3 Subject Characteristics Potential Co-Variables/Modifiers
Patient Demographic Information Demographic Form X X
Patient Numeracy Assessments Schwartz Risk Numeracy Test [27] X
Anemia Symptoms Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F) [28]
X X
Medical Outcomes Patient Electronic Medical Record Hemoglobin Lab Values X X
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trained and oriented to the content and recommended
use of the decision aid.
Data collection, follow-Up, and outcomes
Measures assessed
All participants will be assessed using in-person ques-
tionnaires at baseline before or after their study visit and
at 3 months after enrollment, as described in Table 1.
Changes in patient scores that occur between baseline
pre-visit and after the administration of the ESA deci-
sion aid will be compiled and analyzed. Additionally, all
patients’ medical records will be abstracted for relevant
comorbidities, lab values, medications, and vital signs at
both baseline and 3 month study visits. In this minimal
risk study monitoring for any reported associated ad-
verse events such as anxiety with the educational inter-
vention will be performed throughout its duration by
the PI and study team. All available efforts will be made
to blind outcome survey assessors from group
assignment.
Data management, privacy and monitoring
Data will be entered into a secure online database by the
study coordinator. To protect patient confidentiality,
study-specific identification numbers will be used in the
study database in lieu of participant identifying informa-
tion. Only the PI and the study coordinator will have ac-
cess to the study identification/patient identification link
log, which will be destroyed after study completion. The
PI will monitor data quality and data queries will be re-
solved by the study coordinator. Due to the low risk pro-




The randomly assigned intervention or control group
will be the primary independent variable for intention to
treat analysis. Multiple imputations will be used to han-
dle missing data. Evaluation of the primary outcome of
patient anemia knowledge will be determined by com-
paring intervention and control group Patient Anemia
Knowledge in Kidney Disease (PAKKD) [19] survey
scores between baseline pre-visit and post-visit as well as
baseline pre-visit and 3 months post-intervention for
both study arms. Evaluation of the secondary analyses of
provider communication satisfaction, health decisional
certainty and perceived self-efficacy in patient-provider
communications and patient kidney care will be similarly
measured and analyzed using the Communication As-
sessment Tool (CAT) [20], Decisional Conflict Scale
(DCS) [21] and Perceived Efficacy in Patient-Physician
Interactions (PEPPI) [22] surveys, respectively. Baseline
pre-visit variables will be compared between the study
arms to assess the successfulness of randomization in-
cluding gender, age, education and race, using median
and interquartile ranges for continuous variables and
frequencies and proportion for categorical variables to
ensure homogeneity. Chi-squared tests for categorical
variables and Wilcoxon-rank sum test for continuous
variables will be used to assess the differences in baseline
data between intervention and control. We will use lin-
ear regression models to compare the change in the
PAKKD anemia knowledge scores from baseline to post-
visit and baseline to 3 months post intervention between
the study arms. Baseline pre-visit values of the outcome
variable will be included as a model covariate in linear
regression analysis to compare changes from baseline
pre-visit. Lastly, planned exploratory analyses include
performing logistic regression analysis to assess associ-
ation between the likelihood of achieving or maintaining
hemoglobin targets.
Sample size and power
We are aware of no other previous studies examining
the effectiveness of a shared decision-making interven-
tion designed for the use of ESAs in CKD or ESRD.
Based upon previous experience of using a brief educa-
tional worksheet to improve general kidney knowledge
[23], we estimate a possible doubling or tripling im-
provement in the odds of improved kidney health know-
ledge. For the primary outcome of the PAKKD anemia
knowledge score (range: 0–100 %), preliminary data have
showed a mean (standard deviation) improvement of
59 % (20 %) [19]. Using a t-test for independent samples,
the calculated minimum detectable difference is 11 %
(59 % in control, 70 % in intervention), showing 19 %
relative improvement in anemia knowledge score with
80 % power at a 2-sided significance level. For the pur-
poses of this study, the proposed sample size of 100 par-
ticipants should be adequate and informative.
Discussion
It has been acknowledged from multiple levels of care
and governance that communication of risk and proper
use for ESAs in the treatment of anemia in CKD and
ESRD is an area of concern that must be addressed [24].
We designed the Anemia Risk Communication for pa-
tients with Kidney Disease (ARC-KD) trial to create and
evaluate the effectiveness of a novel ESA decision aid to
assist CKD and ESRD patients and providers in deciding
whether or not to use ESAs to manage anemia related to
underlying kidney disease. Well-designed decision aids
have been shown in randomized controlled trials to im-
prove health knowledge, lower decisional conflict, and
promote accurate risk perceptions for patients living
with a variety of complex health conditions [25]. Deci-
sion aids well-designed to address barriers to ISDM for
Beach et al. BMC Nephrology  (2016) 17:86 Page 8 of 10
vulnerable patient populations, such as patients with
limited health literacy, have been shown to improve pa-
tient knowledge. In diabetics, such aids have even been
implicated in achieving tighter glycemic control [26].
After study completion we will make the decision aid
available via the internet for review by the public and
use by health professionals.
Our study will make advances in a clinically important,
but understudied, area of kidney disease care. It will also
allow us to assess whether this ESA decision aid is asso-
ciated with higher patient knowledge of anemia, as well
as their satisfaction and certainty regarding their deci-
sion to use ESAs. By using the ISDM approach to im-
proving patient understanding of the risks associated
with ESA use in CKD, we hope to mitigate barriers to ef-
fective patient-provider communication such as low
health literacy, and develop a resource for providers to
use cooperatively with their patients. Patient feedback
on the utility of the revised ESA decision aid indicated
kidney disease patients who have only recently started
receiving anemia treatment may receive the maximum
benefit from the implementation of the decision aid tool.
Interestingly, patient feedback also suggested the tool
could be useful in explaining the impact of anemia to
family members. Importantly, as the pharmacologic op-
tions for treatment of anemia in kidney disease expand
in the future, a kidney-specific anemia therapy decision
aid may become a required component of optimized
patient-centered care.
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